We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-25.4%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.39B
AUM Growth
-$1.3B
Cap. Flow
-$296M
Cap. Flow %
-12.4%
Top 10 Hldgs %
47.64%
Holding
157
New
7
Increased
9
Reduced
11
Closed
20

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$25.4M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$20.3M
3
VIGL
Vigil Neuroscience
VIGL
+$14.8M
4
IGMS
IGM Biosciences
IGMS
+$9.31M
5
APLS
Apellis Pharmaceuticals
APLS
+$8.83M

Top Sells

Rank Stock Value
1
FOLD
Amicus Therapeutics
FOLD
+$18.8M
2
NG icon
NovaGold Resources
NG
+$17.8M
3
ALBO
Albireo Pharma Inc
ALBO
+$14M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$12.7M
5
KRYS icon
Krystal Biotech
KRYS
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 90.67%
2 Consumer Discretionary 6.64%
3 Financials 0.85%
4 Consumer Staples 0.31%
5 Industrials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATRA icon
51
Atara Biotherapeutics
ATRA
$70.5M
$9.29M 0.39%
40,000
-20,000
-33% -$6.37M
VERV
52
DELISTED
Verve Therapeutics
VERV
$9.13M 0.38%
400,000
– –
AMAM
53
DELISTED
Ambrx Biopharma Inc
AMAM
$8.87M 0.37%
2,152,291
– –
MRSN
54
DELISTED
Mersana Therapeutics
MRSN
$8.78M 0.37%
88,000
+40,000
+83% +$4.67M
ALXO icon
55
ALX Oncology
ALXO
$261M
$8.45M 0.35%
500,000
– –
SAGE
56
CALL
DELISTED
Sage Therapeutics
SAGE
$8.28M 0.35%
250,000
– –
EXAI
57
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$7.92M 0.33%
550,000
– –
IMUX icon
58
Immunic
IMUX
$177M
$7.91M 0.33%
70,000
– –
VIGL
59
DELISTED
Vigil Neuroscience
VIGL
$7.88M 0.33%
+1,121,191
New +$14.8M
OVID icon
60
Ovid Therapeutics
OVID
$427M
$7.85M 0.33%
2,500,000
– –
SQZ
61
DELISTED
SQZ Biotechnologies Company
SQZ
$7.73M 0.32%
1,606,309
– –
TGTX icon
62
TG Therapeutics
TGTX
$8.27B
$7.61M 0.32%
800,000
– –
OTLY
63
Oatly Group
OTLY
$489M
$7.51M 0.31%
75,000
– –
NBTX
64
Nanobiotix
NBTX
$1.88B
$7.44M 0.31%
1,000,000
– –
OMEG
65
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$7.37M 0.31%
750,000
– –
CYPH
66
Cypherpunk Technologies Inc
CYPH
$64.3M
$7M 0.29%
400,000
– –
SE icon
67
Sea Limited
SE
$66B
$6.89M 0.29%
+57,500
New +$8.1M
TSHA icon
68
Taysha Gene Therapies
TSHA
$1.55B
$6.79M 0.28%
1,040,882
– –
ACHL
69
DELISTED
Achilles Therapeutics
ACHL
$6.63M 0.28%
2,255,375
– –
DSGN icon
70
Design Therapeutics
DSGN
$748M
$6.46M 0.27%
400,000
– –
IMCR icon
71
Immunocore
IMCR
$1.69B
$5.98M 0.25%
200,000
– –
FUSN
72
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$5.83M 0.24%
750,000
– –
CFRX
73
DELISTED
ContraFect Corporation
CFRX
$5.47M 0.23%
18,750
– –
ALPN
74
DELISTED
Alpine Immune Sciences Inc
ALPN
$5.32M 0.22%
593,030
– –
STOK icon
75
Stoke Therapeutics
STOK
$1.81B
$5.26M 0.22%
250,000
– –
1 2
3
4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2022 Portfolio in Review

As of Q1 2022, Artal Group held 157 positions worth $2.39B, down 35% from $3.69B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Artal Group withdrew a net $296M in Q1 2022, closing 20 positions and reducing 11 holdings. Its most notable exit was NovaGold Resources, an estimated $17.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 84% a quarter earlier, followed by Consumer Discretionary and Financials.

Against the trend, Artal Group opened a new position in Vigil Neuroscience worth $7.88M.

  • Artal Group's largest Q1 2022 buy was Vigil Neuroscience: 1,121,191 shares worth $7.88M.
  • Artal Group added most to argenx in Q1 2022, an estimated $25.4M increase.
  • Artal Group's biggest Q1 2022 reduction was Amicus Therapeutics, cutting an estimated $18.8M.
  • Artal Group fully exited NovaGold Resources in Q1 2022, selling an estimated $17.8M.
  • Artal Group's ten largest holdings make up 48% of its $2.39B portfolio in Q1 2022.
  • Artal Group opened 7 new positions and closed 20 in Q1 2022.
  • Artal Group's portfolio value fell 35% quarter-over-quarter to $2.39B.

Based on Artal Group's 13F filing for Q1 2022, filed 12 May 2022.